Furthermore, in clinical trials of NOS inhibition in patients with sepsis, although NOS inhibition ameliorates pathogenic vasodilation and lessens vasopressor requirement, the overall effect is to compromise survival [7]. The gene discussed is NOS1; the disease is Sepsis.